AstraZeneca’s acquisition of Alexion near completion following clearance from European Commission

UK – AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, is finally on course to secure Alexion, a pharma company that specializes in rare disease, following a go-ahead approval from European Commission (EC). The company sought to acquire Alexion for approximately US$39B last year in a bid to establish a specialist rare disease pipeline in its portfolio. EC’s clearance marks an important step towards AstraZeneca’s acquisition of Alexion as the two companies hope to be the leaders in immunology and precision medicines. The proposed acquisition has already received complete clearances…

Read More

European Commission approves Roche’s enspryng as the first and only at home treatment for neuromyelitis optica spectrum disorder

SWITZERLAND – European Commission (EC) has approved Roche’s Enspryng (satralizumab) used to treat adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMOSD treatment that is administered subcutaneously (injection under the skin) every four weeks, allowing home-dosing after appropriate training. The EC approval is supported by results from two Phase III studies, in which ENSPRYNG showed robust and sustained efficacy in reducing the risk…

Read More